| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/22/2009 | EP2050814A1 Compositions for treating multiple sclerosis |
| 04/22/2009 | EP2050763A2 Methods and compositions for modulating vascular integrity |
| 04/22/2009 | EP2050762A2 Novel polypeptides and nucleic acids encoding the same |
| 04/22/2009 | EP2050751A1 Compounds specific to adenosine A1 and A3 receptors and uses thereof |
| 04/22/2009 | EP2050750A2 Multicyclic compounds and their use as inhibitors of PARP, VEGFR2 and MLK3 enzymes |
| 04/22/2009 | EP2050749A1 Pyrimidine derivative as pi3k inhibitor and use thereof |
| 04/22/2009 | EP2050748A1 Novel fused pyrimidines |
| 04/22/2009 | EP2050747A1 Dimers of harmol or of its derivatives and uses thereof |
| 04/22/2009 | EP2050744A1 Quinazoline derivatives as angiogenesis inhibitors |
| 04/22/2009 | EP2050741A1 Crystalline polymorphism of 5-methyl-2-(piperazin-1-yl)benzenesulfonic acid |
| 04/22/2009 | EP2050739A1 Quinazoline derivative |
| 04/22/2009 | EP2050737A1 Mono-and divalent salts of n-(5-hydroxynicotinoil)-l-glutaminic acid exhibiting psychotropic (antidepressant and anxyolytic), neuroprotective, heroprotective and cerebroprotective action |
| 04/22/2009 | EP2050736A1 Imidazole derivatives, processes for preparing them and their uses |
| 04/22/2009 | EP2050734A1 Pentadienamide derivative |
| 04/22/2009 | EP2050468A1 Agent for treatment of cerebral ischemic diseases |
| 04/22/2009 | EP2050467A1 Therapeutic agent for amyotrophic lateral sclerosis |
| 04/22/2009 | EP2050460A1 PYY and agonists thereof for modification of feeding behaviour |
| 04/22/2009 | EP2050459A1 Prophylactic or therapeutic agent for viral disease |
| 04/22/2009 | EP2050458A1 IL24 for inducing hyperproliferative or autoimmune cell death |
| 04/22/2009 | EP2050456A1 Tablet |
| 04/22/2009 | EP2050455A1 Compounds leading to an increase of the IL-12/IL-10 ratio and their use for therapy of infectious and proliferative diseases |
| 04/22/2009 | EP2050454A1 Moisturizing agent |
| 04/22/2009 | EP2050453A1 Pharmaceutical combinations of meloxicam, tramadol and paracetamol |
| 04/22/2009 | EP2050452A1 indenoisoquinolines as topoisomerase inhibitors I useful as antineoplastic agents |
| 04/22/2009 | EP2050451A1 3,11b cis dihydrotetrabanezine for the treatment of psychoses |
| 04/22/2009 | EP2050450A1 1-Piperidine-2-cyanoimino-1,3-dihydro-2H-benzimidazole derivatives as nociceptin analogs with ORL1 modulating activity for the treatment of pain |
| 04/22/2009 | EP2050449A1 Aqueous liquid preparation containing amide compound |
| 04/22/2009 | EP2050448A1 Oral disintegrating tablet having masked bitter taste and method for production thereof |
| 04/22/2009 | EP2050447A1 An entacapone-containing oral dosage form |
| 04/22/2009 | EP2050446A1 Sulfonamide compound or salt thereof |
| 04/22/2009 | EP2050445A2 Pharmaceutical composition of phenofibrate with high bioavailability and method for preparing same |
| 04/22/2009 | EP2050444A1 Fatigue-reducing agent |
| 04/22/2009 | EP2050443A1 Reduction of breast density with 4-hydroxy tamoxifen |
| 04/22/2009 | EP2050442A1 Pharmaceutical composition for prevention and/or treatment of bone disease, functional food or health food comprising the composition, and pharmaceutical preparation comprising the composition as active ingredient |
| 04/22/2009 | EP2050441A1 Use of beta blocker for the manufacture of a medicament for the treatment of hemangiomas |
| 04/22/2009 | EP2050440A1 Stable solid pharmaceutical composition comprising candesartan or pharmaceutically acceptable forms thereof |
| 04/22/2009 | EP2050439A1 Process for production of spherical granule containing slightly water-soluble substance |
| 04/22/2009 | EP2050438A1 Spherical crude granule and method for production thereof |
| 04/22/2009 | EP2050437A1 Improved pharmaceutical dry powder compositions for inhalation. |
| 04/22/2009 | EP2050436A1 Pharmaceutical composition containing dutasteride |
| 04/22/2009 | EP2050435A1 Cough mixture |
| 04/22/2009 | EP2050344A1 Fish feed |
| 04/22/2009 | EP2049899A2 Methods to prevent and treat diseases |
| 04/22/2009 | EP2049664A1 Methods and means for treating dna repeat instability associated genetic disorders |
| 04/22/2009 | EP2049563A2 Dimeric iap antagonists |
| 04/22/2009 | EP2049557A1 1- (-d-glycopyranosyl) - 3 - (4-cyclopropylphenylmethyl) - 4 - halogeno indole derivatives and use thereof as sglt inhibitors. |
| 04/22/2009 | EP2049556A1 New macrolides useful against inflammatory and allergic disseases |
| 04/22/2009 | EP2049548A1 Fused oxazoles & thiazoles as histamine h3- receptor ligands |
| 04/22/2009 | EP2049547A2 Aza-peptide protease inhibitors |
| 04/22/2009 | EP2049546A1 Dihydrofuro pyrimidines as akt protein kinase inhibitors |
| 04/22/2009 | EP2049544A2 Purinone derivatives as hm74a agonists |
| 04/22/2009 | EP2049543A1 Acyclic amine inhibitors of 5'-methylthioadenosine phosphorylase and nucleosidase |
| 04/22/2009 | EP2049540A1 4-amino-3-arylamino-6-arylpyrazolo[3,4-d]pyrimidine derivatives, methods for their preparation and their use as antiviral agents |
| 04/22/2009 | EP2049539A1 Pyrazolopyrimidines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same. |
| 04/22/2009 | EP2049538A1 Novel 1,4-diaza-bicyclo[3.2.2]nonyl pyrimidinyl derivatives and their medical use |
| 04/22/2009 | EP2049537A1 1, 7-naphthyridine derivatives as p38 map kinase inhibitors |
| 04/22/2009 | EP2049536A2 Polycyclic viral inhibitors |
| 04/22/2009 | EP2049534A1 Pyrazolo (3, 4-b) pyridine derivatives as pde4 inhibitors |
| 04/22/2009 | EP2049532A1 Cgrp receptor antagonists |
| 04/22/2009 | EP2049531A2 2-(heterocyclylbenzyl)pyridazinone derivatives |
| 04/22/2009 | EP2049530A2 Crystalline nemorubicin hydrochloride |
| 04/22/2009 | EP2049529A1 Substituted diazepan orexin receptor antagonists |
| 04/22/2009 | EP2049525A1 N-(aminoheteroaryl)-1h-indole-2-carboxamide derivatives, and preparation and therapeutic application thereof |
| 04/22/2009 | EP2049523A1 Modulators of metabolism and the treatment of disorders related thereto |
| 04/22/2009 | EP2049522A2 Hepatitis c virus inhibitors |
| 04/22/2009 | EP2049520A2 Indole compounds |
| 04/22/2009 | EP2049519A2 Cyclic derivatives as modulators of chemokine receptor activity |
| 04/22/2009 | EP2049517A1 Amino-piperidine derivatives as cetp inhibitors |
| 04/22/2009 | EP2049516A2 Pharmaceutical compounds |
| 04/22/2009 | EP2049515A2 Triazolyl pyridyl benzenesulfonamides as ccr2 or ccr9 modulators for the treatment of atherosclerosis |
| 04/22/2009 | EP2049514A1 Nitrate esters of piperidines |
| 04/22/2009 | EP2049513A1 Pieridinyl substituted pyrrolidinones as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 |
| 04/22/2009 | EP2049512A2 Crystalline duloxetine hydrochloride |
| 04/22/2009 | EP2049511A1 Use of coumarin derivatives in antifungal therapy |
| 04/22/2009 | EP2049510A1 Process for the preparation of candesartan cilexetil form i |
| 04/22/2009 | EP2049506A2 Modulators of pharmacokinetic properties of therapeutics |
| 04/22/2009 | EP2049505A2 Isoform-selective hdac inhibitors |
| 04/22/2009 | EP2049503A1 Quinazoline and pyridopyrimidine derivatives as p38 kinase inhibitors |
| 04/22/2009 | EP2049502A1 2,4-substituted quinazolines as lipid kinase inhibitors |
| 04/22/2009 | EP2049501A1 Hydroxylated and methoxylated cyclopenta [d] pyrimidines as akt protein kinase inhibitors |
| 04/22/2009 | EP2049500A1 Cyclopenta [d] pyrimidines as akt protein kinase inhibitors |
| 04/22/2009 | EP2049498A1 Pyrimidine compounds for combating pathogenic fungi and cancer |
| 04/22/2009 | EP2049495A2 N-aryl or n-heteroaryl pyrazolidine and pyrazolidinone derivatives as prostaglandine receptor inhibitors |
| 04/22/2009 | EP2049493A2 Compounds suitable as modulators of hdl |
| 04/22/2009 | EP2049491A1 Heteroaryl compounds useful as inhibitors of e1 activating enzymes |
| 04/22/2009 | EP2049490A1 N-(benzoyl)-o- [2- (pyridin- 2 -ylamino) ethyl]-l-tyrosine derivatives and related compounds as a5b1 antagonists for the treatment of solid tumors |
| 04/22/2009 | EP2049486A2 Piperidinyl derivatives as modulators of chemokine receptor activity |
| 04/22/2009 | EP2049485A1 Naphthalene derivatives used as ep4 receptor agonists |
| 04/22/2009 | EP2049484A1 Isoindoline derivatives for the treatment of arrhythmias |
| 04/22/2009 | EP2049483A2 Inhibitors of histone deacetylase |
| 04/22/2009 | EP2049481A2 Novel compounds as antagonists or inverse agonists for opioid receptors |
| 04/22/2009 | EP2049480A1 2-arylindole derivatives as npges-i inhibitors |
| 04/22/2009 | EP2049479A2 Polymorphs of atorvastatin sodium and magnesium salts |
| 04/22/2009 | EP2049478A1 Substituted n-phenylmethyl -5-oxo-proline-2-amides as p2x7-receptor antagonists and their methods of use |
| 04/22/2009 | EP2049477A2 Modulators of chemokine receptor activity, crystalline forms and process |
| 04/22/2009 | EP2049475A1 Cyclohexyl substituted pyrrolidinones as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 |
| 04/22/2009 | EP2049473A2 Substituted benzyl amine compounds |
| 04/22/2009 | EP2049472A2 Cyclopropyl amine derivatives as histamin h3 receptor modulators |
| 04/22/2009 | EP2049467A2 Therapeutic amides and related compounds |
| 04/22/2009 | EP2049466A1 Butyl and butynyl benzyl amine compounds |